Holding of core competence for precision medicine era
The paradigm of future medicine in the fourth
industrial revolution era is shifting with personalized “precision medicine” at the center. Theragen Etex group receives more attention
because it has both gene analysis ability and personalized drug development capability, which are core technologies for “precision
The world’s highest level of genome analysis technology
Theragen Bio has made excellent achievements
using innovative technologies such as the creation of the world’s first female/tiger/minke whale genome maps and completion of the
first domestic human genome map, holding the largest domestic genome analysis performance, and first commercialization of individual
genome analysis service in Asia. The company is now poised to benefit from the new growth engine.
International GMP certified facilities, stable manufacturing and supply of medicines
Theragen Etex increased production facilities, acquired GMP certification from international consultative group, Pharmaceutical Inspection
Cooperation/Scheme (PIC/S), and now stably manufactures and supplies medicines with its distribution affiliated companies. It also
actively conducts research for securing a new drug pipeline such as incrementally modified drugs (IMD) or orphan drugs.
Carcinogenic gene analysis and development of novel anticancer drug
With the cooperation of the world’s
best research institutes and medical staff, we analyze variations in carcinogenic genes such as stomach cancer, liver cancer, head
and neck cancers, and breast cancer and disease mechanisms. Vactosertib, a novel anticancer drug that we are developing, is under
clinical trial in Korea and the US.
About Us Group companies make efforts to achieve a healthier and happier tomorrow.
Medpacto, confirmation of efficacy in the clinical study on “Vactosertib” colon cancer & lung cancer
Medpacto, which is a subsidiary of TheragenEtex, officially reported the initial results of Clinical Test 1b∙2a of Vactosertib (TEW-7197).
While attending the “Society for Immunotherapy of Cancer (SITC) 2019” which wa...
TheragenEtex conducts ‘genetic research on diseases after renal transplantation’ organized by the Kyung Hee University Hospital at Gangdong
TheragenEtex Bio Institute, together with the Kyung Hee University Hospital at Gangdong, conducted research in order to discover and confirm genetic markers for the prediction of chronic diseases that can occur after ren...
TheragenEtex, publication of thesis on the “age distributions of facial metrics in Koreans by age”
TheragenEtex Bio Institute published the results of a study titled, “The age distribution of facial metrics in two large Korean populations” in “Scientific Reports,” a sister journal of “Nature.”
The results of this r...
TheragenEtex, publication of thesis on “relationship between gastric microbiota and gastric cancer”
TheragenEtex Bio Institute published the results of a study titled, “Association between the relative abundance of gastric microbiota and the risk of gastric cancer: a case-control study,” which was conducted together wi...
Regulations hamper industry's bid to expand home test
By Nam Hyun-woo
SUWON, Gyeonggi Province ― Six years ago, actress Angelina Jolie revealed that she had a preventive double mastectomy, after genetic tes...
MedPacto Passes Technology Assessment, the Next Goal Is Listing on KOSDAQ within This Year
MedPacto, a subsidiary of TheragenEtex, has passed the technology assessment required for listing on KOSDAQ and is promoting special listing for technology.
In recently conducted technology assessment, MedPacto r...